Under the terms of the contract, the state will pay a fixed dollar amount to AbbVie for an unlimited supply of hepatitis C drugs.
The contract is part of the state’s plan to eliminate hepatitis C by 2030.
Last month, the state of Louisiana struck a deal with a Gilead Sciences subsidiary to supply hepatitis C medication under a subscription-style payment model.
Both Washington and Louisiana plan to start their programs this summer.
More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
